CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ABBV

BIIB019 (Daclizumab High Yield Process)

Phase 2
AbbVie Inc. (ABBV)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsing-Remitting Multiple Sclerosis

View Full Landscape
Drug Information

Target Indication

Relapsing-Remitting Multiple Sclerosis

Clinical Trial

NCT00390221

Last updated: 11/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA7/1/2016

Zinbryta

Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.